3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
2
Stomach Neoplasms
1
Psychological Well-Being
1
Pancreatic Neoplasms
1
Motor Activity
1
Lung Neoplasms
1
Liver Neoplasms
1
Leiomyoma
1
Inflammation
1
Esophageal Neoplasms
1
Carcinoma, Hepatocellular
1
Agnosia
1
Abdominal Cancer
1
Interventions
Cisplatin
31
Fluorouracil
24
Paclitaxel
19
Radiotherapy
15
Docetaxel
11
Esophagectomy
8
Radiation
7
Neoadjuvant Therapy
7
Carboplatin
7
Irinotecan
6
Oxaliplatin
5
Leucovorin
5
Capecitabine
5
sintilimab
4
pembrolizumab
4
camrelizumab
4
TP protocol
4
Surgical Procedures, Operative
4
Drug Therapy
4
Chemotherapy, Adjuvant
4
Trastuzumab
3
Immunotherapy
3
Epirubicin
3
Chemoradiotherapy
3
tislelizumab
2
nimotuzumab
2
S 1 (combination)
2
Radiotherapy, Adjuvant
2
Platinum Compounds
2
Nivolumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Esophageal Neoplasms
×
Tea
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled